MedTrace Logo

Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients

NCT00031473 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2010-08-27

No results posted yet for this study

Summary

The purpose of this study is to test the safety and effectiveness of ribavirin, administered as an aerosol, in preventing progression of upper respiratory tract RSV infection to RSV pneumonia in bone marrow and peripheral blood transplant recipients.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

Virazole (Ribavirin) Inhalation Solution

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-11-30
Completion
2003-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00031473 on ClinicalTrials.gov